.png){kind=icon}
返回
Fesoterodine
.png){kind=icon}
PRE
AI
DOI：10.2165/00003495-200969060-00006.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Fesoterodine is a muscarinic receptor antagonist that is rapidly and extensively converted to the active and more potent metabolite 5-hydroxy-methyltolterodine. The drug is approved for once-daily oral administration in patients with overactive bladder syndrome (OAB). In two large, 12-week, randomized, double-blind, multicentre, phase III trials, oral fesoterodine 4 or 8 mg once daily improved the symptoms of OAB (frequency of micturition, urgency and urge incontinence) significantly more than placebo. Furthermore, significantly more patients receiving fesoterodine 4 or 8 mg once daily had a positive response to therapy than those receiving placebo, as determined by a treatment questionnaire. Health-related quality of life was improved to a significantly greater extent in patients with OAB who received fesoterodine 4 or 8 mg once daily than in those who received placebo in a post hoc analysis of pooled data from the phase III trials. Fesoterodine 4 or 8 mg once daily was generally well tolerated in patients with OAB; the most frequent adverse event was dry mouth, which was generally mild to moderate in severity.
Keyword:
OVERACTIVE BLADDER SYNDROME
TOLERABILITY
EFFICACY
SAFETY
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
Impact of fesoterodine on quality of life: pooled data from two randomized trials.png)
BJU INTERNATIONAL
BJU INTERNATIONALIF4.4
PREAI
分享收藏Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study五个国家基于人群的尿失禁、膀胱过度活动症和其他下尿路症状调查: EPIC研究结果EUROPEAN UROLOGY
EUROPEAN UROLOGYIF25.2
PREAI
分享收藏Improving the tolerability of anticholinergic agents in the treatment of overactive bladderDRUG SAFETY
DRUG SAFETYIF3.8
PREAI
分享收藏Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivoBJU INTERNATIONAL
BJU INTERNATIONALIF4.4
PREAI
分享收藏Particulate metal exposures induce plasma metabolome changes in a commuter panel studyPLOS ONE
OAAI
PLOS ONEIF0
OAAI分享收藏
查看更多内容